Characterization of polymorphs and hydrates of GK-128, a serotonin, receptor antagonist

International Journal of Pharmaceutics

Volumn 151, Issue 2, 1997, Pages 133-142

  Ito, S ^a   Nishimura, M ^a   Kobayashi, Y ^a   Itai, S ^a   Yamamoto, K ^a  

^a TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

GK 128; Hemihydrate; Intrinsic dissolution rate; Monohydrate; Polymorphic form; Powder X ray diffraction; Transitional temperature

Indexed keywords

2 [(2 METHYL 1 IMIDAZOLYL)METHYL]BENZO[F]THIOCHROMEN 1 ONE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DISSOLUTION; DRUG SOLUBILITY; HUMIDITY; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; THERMAL ANALYSIS; X RAY DIFFRACTION;

EID: 0030997813     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)04867-9     Document Type: Article

References (25)

1. Behme, R.J., Brooke, D., Farney, R.F. and Kensler, T.T., Characterization of polymorphism of gepirone hydrochloride. J Pharm. Sci., 74 (1985) 1041–1046.
2. Burger, A. and Ramberger, R., On the polymorphism of pharmaceuticals and other molecular crystals. I. Mikrochim. Acta [Wien], II (1979) 259–271.
3. Carlton, R.A., Difeo, T.J., Powner, T.H., Santos I. and Thompson, D., Preparation and characterization of polymorphs for an LTD4 antagonist, RG12525. J. Pharm. Sci., 85 (1996) 461–467.
4. Chauvet, A., Masse, J., Ribet, J.P., Bigg, D. Autin, J.M., Maurel, J.L., Patoiseau, J.F. and Jaud, J., Characterization of polymorphs and solvates of 3-amino-1-( m -trifluoromethylphenyl)-6-methyl-1 H -pyridazin-4-one. J. Pharm. Sci., 81 (1992) 836–841.
5. Drennen, J.K. and Lodder, R.A., Nondestructive near-infrared analysis of intact tablets for determination of degradation products. J. Pharm. Sci., 79 (1990) 622–627.
6. Ghodbane, S. and McCauley, J.A., Study of the polymorphism of 3-((3-(2-(7-chloro-2-quinolinyl)-( E )-ethenyl)phenyl)((3-(dimethylamino-3-oxopropyl)thio) methyl)thio)propanoic acid (MK571) by DSC, TG, XRPD and solubility measurements. Int. J. Pharm., 59 (1990) 281–286.
7. Haleblian, J. and McCrone, W., Pharmaceutical applications of polymorphism. J. Pharm. Sci., 58 (1969) 911–929.
8. Haleblian, J.K., Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci. , 64 (1975) 1269–1288.
9. Ikeda, Y., Nishijima, K., Tokai, N. and Nishi, K., Kinetic studies of transition of seratrodast polymorphic forms by differential scanning calorimetry. Yakugaku Zasshi, 115 (1995) 937–943.
10. Ito, C., Isobe, Y., Kijima, H., Kiuchi, Y., Ohtsuki, H., Kawamura, R., Tsuchida, K. and Higuchi, S., The anti-emetic activity of GK-128 in Suncus murinus . Eur. J. Pharmacol., 285 (1995) 37–43.
11. Jozwiakowski, M.J., Williams, S.O. and Hathaway, R.D., Relative physical stability of the solid forms of amiloride HCl. Int. J. Pharm., 91 (1993) 195–207.
12. Kaneniwa, N., Yamaguchi, T., Watari, N. and Otsuka, M., Hygroscopicity of carbamazepine crystalline powders. Yakugaku Zasshi, 104 (1984) 184–190.
13. Kitamura, S., Chang, L. and Guillory, J.K., Polymorphism of mefloquine hydrochloride. Int. J. Pharm., 101 (1994) 127–144.
14. Kitaoka, H., Wada, C., Moroi, R. and Hakusui, H., Effect of dehydration on the formation of levoflaxacin pseudopolymorphs. Chem. Pharm. Bull., 43 (1995a) 649–653.
15. Kitaoka, H., Ohya, K. and Hakusui, H., Thermal dehydration of nafagrel hydrochloride hydrate at controlled water vapor partial pressures. Chem. Pharm. Bull., 43 (1995b) 1744–1750.
16. Mewada, G.S., Parikh, D.R. and Somasekhara, S., Polymorphism in pharmaceuticals. Sci. Cult., 39 (1973) 378–383.
17. Nogami, H., Nagai, T. and Yotsuyanagi, T., Dissolution phenomena of organic medicinals involving simultaneous phase changes. Chem. Pharm. Bull., 17 (1969) 499–509.
18. Ozawa, T., A new method of analysing thermogravimetric data. Bull. Chem. Soc. Jpn. , 38 (1965) 1881–1886.
19. Randall, C.S., DiNenno, B.K., Schultz, R.K., Dayter, L., Konieczny, M. and Wunder, S.L., Solid-state transformation of a leukotriene antagonist. Int. J. Pharm., 120 (1995) 235–245.
20. Shefter, E. and Higuchi, T., Dissolution behavior of crystalline solvate and nonsolvated forms of some pharmaceuticals. J. Pharm. Sci., 52 (1963) 781–792.
21. Suryanarayanan, R. and Mitchell, A.G., Phase transitions of calcium gluceptate. Int. J. Pharm., 32 (1986) 213–221.
22. Uchida, T., Yonemochi, E., Oguchi, T., Terada, K., Yamamoto, K. and Nakai, Y., Polymorphism of tegafur: physico-chemical properties of four polymorphs. Chem. Pharm. Bull., 41 (1993) 1632–1635
23. Wadke, D.A. and Jacobson, H., Preformulation testing. In Liberman. H.A. and Lachman, L. (Eds.), Pharmaceutical Dosage Forms: Tablets , 1980, p. 1.
24. Yamada, T., Ikegami, K., Toda, M., Saito, N., Iizuka, K. and Otagiri, M., Polymorphism of 3,9-bis-( N , N -dimethylcarbamoyloxy)-5 H -benzofuro[3,2- C ]quinoline-6-one (KCA-098), a new benzofuroquinoline derivative. Yakugaku Zasshi, 115 (1995) 978–984.
25. York, P., Solid-state properties of powders in the formulation and processing of solid dosage forms. Int. J. Pharm., 14 (1983) 1–28.